利伐沙班治疗非瓣膜病心房颤动的安全性及疗效

摘要

目的:探讨利伐沙班治疗非瓣膜病心房颤动(AF)的安全性及疗效.方法:77例非瓣膜病AF患者按患者及家属的意愿随机分为两组,A组40例,给予利伐沙班治疗,B组37例,给予华法林治疗.比较两组患者治疗后的临床疗效、身体状况、不良事件发生情况.结果:①临床疗效:A组临床总有效率明显高于B组,P＜0.05.②不良事件:两组缺血性卒中发生率、体循环栓塞发生率比较无明显差异,P＞0.05;A组发生出血事件,显著低于B组,P＜0.05.③治疗后,两组患者的血糖、白细胞计数、尿素氮等水平与治疗前的比较基本无差异,治疗后两组各个指标间比较也基本无差异,P＞0.05.结论:非瓣膜病AF患者用利伐沙班治疗的安全性较高、疗效好.%Objective:To investigate the safety and efficacy of rivaroxaban in the treatment of non valvular atrial fibrillation (AF).Methods:77 patients with non valvular AF were randomly divided into two groups according to the wishes of patients and their families,A group of 40 cases,given rivaroxaban treatment,B group of 37 cases,given warfarin treatment.The clinical efficacy,physical condition and adverse events were compared between the two groups.Results:①Clinical total effective rate:A group was significantly higher than that of B group,P ＜0.05.②)There was no significant difference between the two groups in the incidence of ischemic stroke and the incidence of systemic embolism,P ＞0.05;A group bleeding events were significantly lower than those in B group P ＜0.05.③After treatment,the two groups of patients with blood glucose,white blood cell count,urea nitrogen and other levels before and after treatment,no difference between the two groups after treatment,there was no difference between the various indicators,P ＞0.05.Conclusion:Rivaroxaban is safe and effective in the treatment of patients with non valvular AF.